Shots:
- BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.
- BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient wound care while building strong distributor-led partnerships that create a differentiated and scalable model, minimizing competition and maximizing market impact.
- PharmaShots welcomes Jaime Leija, President, CEO and Co-Founder at BioLab Holdings for an insightful and engaging conversation on leadership, patient-first innovation, and the evolving future of advanced wound care.
Saurabh: BioLab’s mission emphasizes redefining patient care through innovation! How do you balance long‑term scientific breakthroughs with the need to deliver products that address immediate clinical needs?
Jaime: What really drives BioLab’s product development is our wound care continuum, which clearly identifies opportunities to bring meaningful products and resources to clinicians and patients. We take a very balanced approach, looking at line extensions of existing products, combining platforms to get products to market quickly and efficiently, and scouting FDA‑approved products that have little to no commercialization. A great example is Imbed from Microlyte: it was already FDA approved and we saw an opportunity to help increase the distribution and utilization of this product, which is our strong suit, so we partnered, secured exclusive licensing and distribution, and invested further in the technology. At the same time, we’re supporting longer‑term initiatives like cureVision, terraplasma, and Dermistat to continue building a best‑of‑breed continuum that meets both immediate and future clinical needs.
Saurabh: As a rapidly growing medical manufacturer in advanced wound care, what would you say has been the most transformative strategic decision the leadership team has made in the last 3 years?
Jaime: I’d say it comes down to two transformative decisions. First, we were extremely refined and disciplined in our approach to the market, rather than trying to boil the ocean, we stayed very focused on chronic, non‑healing wounds in the outpatient wound care space, which allowed us to concentrate our resources, clearly define the patient profile, and limit our competition. That focus gave us a real fighting chance, especially compared to going after the inpatient space and competing with industry heavyweights, which honestly would have put us out of business. Second, we made a very deliberate decision to sell only through wholesalers and distributors, treating them as the customer and building true partnerships, which eliminated channel conflict and became a key differentiator that has driven our success today.
Saurabh: With leaders drawn from diverse backgrounds from science and finance to commercial operations and innovation; how do you foster alignment across teams to ensure shared focus on BioLab’s core values (e.g., collaboration, integrity, impact)?
Jaime: This is probably the biggest challenge for any company: how you take very different leadership personalities and get them to work collectively and cohesively while maintaining alignment around core values. It starts with recruiting for balance, not sameness, by bringing in people with diverse backgrounds who complement each other’s strengths and weaknesses, which ultimately makes us a stronger organization. Once that foundation is in place, it’s critical that we are routinely reminded of and reassessing our core values to ensure they stay relevant to the company’s goals and the direction of the industry. That ongoing work—making sure strong, experienced leaders have the tools, resources, and dialogue they need to build productive relationships that support our values, is one of my biggest responsibilities as CEO.
Saurabh: BioLab places a strong emphasis on care and impact. Can you share an example of how your internal culture has directly influenced product decisions or strengthened partnerships with healthcare providers?
Jaime: Over years of talking with clinicians, we learned how frustrating it is for them that they can’t extend these worldclass products to every patient, especially those without insurance. That was something that really kept them up at night, so instead of just listening, we decided to do something about it by creating our Charity Care initiative. Through this program, we’re able to donate product to uninsured patients, using a formal program and a nonreimbursable product label to navigate the complexities of our insurance system.
Saurabh: BioLab’s R&D team works on integrating biomaterial science with regenerative medicine. What are the biggest scientific or clinical challenges you’re tackling right now, and how do you prioritize where to invest your innovation resources?
Jaime: Our biggest challenge is organizing and prioritizing the many different ways product development can happen, especially given that we’re a very flat organization despite having a large impact and the biggest share in our sector of wound care. We’re a fraction of the size of the companies we compete with, so when opportunities present themselves—whether through acquisition or licensing, line extensions across our existing product lines, combining platforms, or pure R&D—we have to be extremely disciplined about where we focus our resources. There are a lot of different paths to bringing new products and technologies into the company, and we can’t pursue all of them at once. The challenge is creating a method to evaluate those opportunities and decide which investments will drive the most value for our stakeholders, starting with the patient, and extending to providers, clinics, insurers, and distributors.
Saurabh: With strategic investments and partnerships in advanced technologies (e.g., AI diagnostics, synthetic matrices), how do you assess which external innovations will best complement BioLab’s internal capabilities?
Jaime: Over the last couple of years, we’ve evolved a formal way to vet ideas without ever stifling innovation, knowing that great ideas don’t just come from R&D but from employees, distributors, clinicians, and even complementary industries. We built a BioLabspecific product lifecycle process that starts with a large idea-creation funnel and first filters on one simple question: does this provide real value to clinicians and patients, as determined by our medical leadership. From there, sales operations evaluates reimbursement and profitability across the entire ecosystem, and if it clears that hurdle, our science and technology team determines the best path forward, whether that’s licensing, acquisition, exclusive distribution, or internal development. That process helps us narrow many ideas into a few focused initiatives while ensuring the IP is sound and the investment drives meaningful value.
Saurabh: Healthcare markets and reimbursement landscapes are continually shifting. How does BioLab approach adapting its product strategy and commercial model in response to changes in provider needs or payer frameworks?
Jaime: Healthcare markets and reimbursement landscapes are constantly shifting, and while that’s a market force we don’t control, it’s critical that we have a voice wherever possible. We do that through active participation in key alliances, which gives us access to Medicare and the FDA and allows us to provide feedback, data, and consultation as policies and reimbursement frameworks change. Just as important is maintaining flexibility—being lean as an organization allows us to pivot quickly in ways much larger competitors simply can’t. That flexibility extends to our portfolio, where we can pull products off the market or hold FDAcleared, reimbursable products in reserve and reintroduce them when the regulatory and reimbursement environment stabilizes.
Saurabh: What role do global collaborations and distribution partnerships play in your growth strategy, especially as you seek broader impact for wound‑care solutions?
Jaime: As we scout partners, one of the key things we look for is companies that already have distribution outside the U.S., knowing that long term we want to expand beyond our stronghold in outpatient wound care and into inpatient and global markets. We haven’t gone global sooner because while the U.S. represents only about 4% of the population, it accounts for roughly 48% of wound care spend, which is why so many nonU.S. companies are trying to enter this market first. Global markets require a very different, more socialized approach, with different payers and sites of service, so we’ll need to lean on partners like cureVision, terraplasma, and Microlyte who already have experience in those regions. A good example is terraplasma, where we’re leveraging their AsiaPacific distribution to run controlled pilot programs that generate clinical evidence and white papers we can later use as we bring the full platform back into the U.S.
Saurabh: From the executive perspective, what does a truly “patient‑first” philosophy look like beyond product development, especially in terms of clinical support, education, and outcomes measurement?
Jaime: At the core of everything we do is the patient’s best interest, and that starts with quality and compliance. Every product has to meet those standards first so we can deliver safe, effective solutions that truly help patients heal. Even though we don’t work with patients directly, without their medical need there would be no reason for us to exist. That’s why everything we do is focused on supporting the doctor, helping patients get better faster and more completely, and ultimately being a value to the insurance company as well.
Saurabh: As BioLab scales, how do you ensure that the patient’s voice remains central in strategic decisions and company priorities? For example, how do you incorporate real‑world feedback from clinicians and patients into product refinement?
Jaime: In wound care, the voice of the customer is really the provider, not the patient, which means we have to be very intentional about actively soliciting feedback and spending time in the field with clinicians. Our medical advisory group plays a critical role in validating the technologies we use and ensuring they address realworld clinical needs. Tools like cureVision will help accelerate that process by quickly capturing and disseminating data from the point of care, allowing providers to leverage objective information in real time. That data supports faster protocols, better decisionmaking, and ongoing treatment tracking to inform the right recommendations at the right moment.
About Jaime Leija
Jaime Leija co-founded BioLab Holdings and serves as President & Chief Executive Officer, bringing over 20 years of experience in sales leadership, marketing, and operations. Prior to BioLab, Mr. Leija held the position of Region Vice President of Sales for IKON Office Solutions, AOT-Xerox, and Advance Laboratory Consultants. Beyond his professional commitments, Mr. Leija is passionate about youth sports and their role in shaping the lives of young people. Together with his wife and family, Mr. Leija runs a non-profit organization, The Competitive Youth Sports Foundation of Arizona, which helps low to moderate-income families have access to sports teams, camps, and equipment.
Related Post: When Algorithms Decide Visibility: Ben Beckley, CEO of RevHealth on the Future of Pharma
